91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

语言

切换导航

我的购物车

搜索

语言

首页
药靶配体
配体家族
免疫检查点调节剂
Sugemalimab (anti-PD-L1)

Sugemalimab (anti-PD-L1)

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

种属反应性: Human
亚型: Human IgG4SP

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货	价格	数量
Ab175662-1mg	1mg	期货
Ab175662-5mg	5mg	期货
Ab175662-10mg	10mg	期货

Skip to the end of the images gallery

main product photo

Skip to the beginning of the images gallery

基本信息

产品名称	Sugemalimab (anti-PD-L1)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	CD274
反应种属	Human

产品属性

Format	Whole IgG
亚型	Human IgG4SP
轻链亚型	Lambda
SDS-PAGE	143.36 kDa
纯化方法	Protein A purified
物理外观	Liquid
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 18 months.?Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	2256084-03-2

数据库链接

IMGT/mAb-DB	1031

关联配体

Ligand ID	12342
名称	sugemalimab
别名	Cejemly® (China)
类别	Antibody
学名	4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价	The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).
评价	Sugemalimab is a fully human, high-affinity anti-programmed death ligand 1 (PD-L1) IgG4 monoclonal antibody. It is a checkpoint inhibitor class immuno therapeutic. In vitro, it competitively blocks the binding of human PD-L1 to PD-1 and CD80, and it induces T lymphocyte proliferation and enhances antitumour immunity .
配体家族	Immune checkpoint modulators
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰
临床描述	This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors. This is a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of CS1001 in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.
来源公司	CStone Pharmaceuticals CStone Pharmaceuticals

参考文献

1. Dhillon S, Duggan S. (2022) Sugemalimab: First Approval.. Drugs, 82 (5): (593-599). [PMID:35298827]
2. Gong J, Cao J, Zhang Q, Xu N, Zhao Y, Xing B, Miao Z, Wu Y, Pan H, Gao Q et al.. (2022) Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.. Cancer Immunol Immunother, 71 (8): (1897-1908). [PMID:34984540]

相关文档

质检报告COA

请输入批号:

SDS中文版 SDS英文版

质量技术规格说明书

产品问答

产品问答

登录提交问题

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

上海阿拉丁生化科技股份有限公司

销售条款及条件 ? ? ? ? 隐私政策

? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任

沪公网安备 31012002004058号沪ICP备09093490号-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

危险品化学品经营许可证（带存储）

营业执照(三证合一)